alexa Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Obesity & Weight Loss Therapy

Author(s): Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T,

Abstract Share this page

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM, we determined the impact of 6 months' GLP-1 RA therapy on intrahepatic lipid (IHL) in obese, T2DM patients with hepatic steatosis, and evaluated the inter-relationship between changes in IHL with those in glycosylated haemoglobin (HbA(1)c), body weight, and volume of abdominal visceral and subcutaneous adipose tissue (VAT and SAT). We prospectively studied 25 (12 male) patients, age 50±10 years, BMI 38.4±5.6 kg/m(2) (mean ± SD) with baseline IHL of 28.2\% (16.5 to 43.1\%) and HbA(1)c of 9.6\% (7.9 to 10.7\%) (median and interquartile range). Patients treated with metformin and sulphonylureas/DPP-IV inhibitors were given 6 months GLP-1 RA (exenatide, n = 19; liraglutide, n = 6). IHL was quantified by liver proton magnetic resonance spectroscopy ((1)H MRS) and VAT and SAT by whole body magnetic resonance imaging (MRI). Treatment was associated with mean weight loss of 5.0 kg (95\% CI 3.5,6.5 kg), mean HbA(1c) reduction of 1·6\% (17 mmol/mol) (0·8,2·4\%) and a 42\% relative reduction in IHL (-59.3, -16.5\%). The relative reduction in IHL correlated with that in HbA(1)c (ρ = 0.49; p = 0.01) but was not significantly correlated with that in total body weight, VAT or SAT. The greatest IHL reduction occurred in individuals with highest pre-treatment levels. Mechanistic studies are needed to determine potential direct effects of GLP-1 RA on human liver lipid metabolism.
This article was published in PLoS One and referenced in Journal of Obesity & Weight Loss Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 13th World Congress on Obesity
    Aug 24-25, 2017, Toronto, Canada
  • 13th Euro Obesity and Endocrinology Congress
    Sep 21-23, 2017, Madrid, Spain
  • 14th Global Obesity Meeting
    Oct 23-24, 2017 Dubai, UAE
  • 16th International Conference and Exhibition on Obesity & Weight Management
    November 13-15, 2017 Atlanta,Georgia, USA

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version